Global Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User, By Regional Outlook and Forecast, 2022-2028

The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.

Gene therapy is the process of replacing faulty or damaged genes at the molecular level. It is a procedure in which viruses are genetically modified before being transmitted to host cells. Viruses are genetically modified to contain a gene that is now frequently used to cure cancer. The pipeline for cancer gene therapy is quite strong, and various industry participants have recently concentrated their efforts on developing a number of successful cancer gene therapies and vectors. Pre-marketing approval is required for the marketing of cancer gene therapy, and it is a lengthy process that is closely reviewed. As a result, there are few cancer gene treatments on the market, and they are still in development. However, vectors, which are essential for gene transfer and are pre-requisites for gene therapy, are increasingly being used in study and treatment.

Cancer is described as uncontrolled cell development in the body that results in organ failure. It can be fatal if left untreated. The body manages uncontrolled cell proliferation in numerous ways, one of which is by deploying white blood cells to detect and kill malignant cells. The immune system has been discovered to be influenced in order to cause malignant cells to self-destruct. The effects of radiation and chemotherapy therapy on malignant cells in the body are constant and dependable. Immunotherapy for hematological tumors has recently gained popularity and is attracting the attention of numerous researchers. Scientists have devised a method for isolating, replicating, and developing cancer-destroying cells from a patient's blood cancer and then injecting those cells back into the patient to eliminate their tumors, resulting in long-term remissions.

Cancer has a strong tendency to spread throughout the body. It is the world's second-leading cause of death. Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene. Cancer gene therapy has grown in popularity as a result of its high success rate in preclinical and clinical trials. A treatment in which the mutant gene is replaced with a healthy gene or the deactivation of a gene whose function is improper are examples of cancer gene therapy procedures. A new strategy for combating cancer cells has just been devised, in which new genes are delivered into the body.

COVID-19 Impact Analysis

The COVID-19 pandemic has hampered the market for cancer gene therapy. Doctors from Dana Farber Cancer Institute discovered that during the COVID-19 pandemic, there was a 46 percent decline in diagnoses of the six most frequent cancer types-breast, pancreatic, colorectal, lung, gastric, and oesophageal cancers, according to research published in Cancer Connect 2020. Furthermore, the Centres for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health-prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits, in order to secure hospital infrastructure for COVID-19 patients" treatment. As a result, the COVID-19 pandemic has had an influence on the market for cancer gene therapy.

Market Growth Factors

Growing cases of Cancer

In recent years, there has been a rising burden of cancer disease, the expanding focus on research to create an effective cancer treatment, and growing investments in cancer research. According to Globocan 2020, an expected 19,292,789 new cancer cases and 9,958,133 cancer-related deaths were reported worldwide in 2020. Various gene therapy strategies are now being used in the treatment of cancer. Anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, gene therapy-based immune modulation, oncolytic virotherapy, gene correction/compensation, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi techniques are only a few examples. These medicines have been used to treat cancers such as brain, lung, breast, pancreas, liver, prostate, colorectal, bladder, head & neck, skin, ovarian, and renal cancer.

Supportive regulations

An improving regulatory landscape is expected to help the industry players to optimize the opportunities. In addition, manufacturers are subject to regulations to secure the admission of defect-free products (vectors) onto the market, as they are associated with people's health. Because any flaws in gene therapy goods could be lethal to patients, laws have been changed to ensure that no products are recalled during post-market surveillance. Better success rates of novel medicines, ethical acceptance of gene therapy for cancer treatment, and enormous unexplored markets in emerging nations are expected to impact the market in the long run.

Marketing Restraining Factor:

High cost of Cancer Gene Therapy

Gene therapy can be very expensive, thereby discouraging many people from choosing this mode of treatment. In the United States, for example, Zolgensma, gene therapy for spinal muscular atrophy, is the most expensive drug. In many countries, people have low disposable income, so spending high costs on healthcare is still a distant dream for them. Moreover, many governments are reeling from the negative impacts brought by the COVID-19 pandemic on their economy and healthcare infrastructure. The high expense of cancer gene therapy is due to the need for extensive clinical studies; also, unlike other pharmaceuticals, treatment by cancer gene therapy varies from person to person depending on the genetic acceptance of each patient.

Therapy Outlook

Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. In 2021, the Gene Transfer segment held a promising revenue share of the Cancer Gene Therapy Market. Gene transfer is a new treatment method that involves introducing new modified genes into malignant cells or associated tissue in order to kill the cells or restrict their growth. This method is adaptable, as it may be employed with a wide range of vectors and genes in clinical trials with positive results. Gene therapy could be utilized alone or in combination with other treatments to control the condition as technology advances. Naked/plasmid vectors, electroporation, sonoporation, magnetoreception, and gene gun are all used to transfer or replace genes.

End User Outlook

Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. In 2021, the hospital segment collected the maximum revenue share of the Cancer Gene Therapy Market. This is owing to rising healthcare awareness, an increase in the number of hospitals, and an increase in the geriatric and bariatric populations. Therefore, these factors is expected to continue to boost the growth of the segment even during the forecasting period.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, the North America emerged as the leading region in the overall Cancer Gene Therapy Market by procuring the highest revenue share of the market. The growth of the regional market is owing to the huge investments in research and technological breakthroughs. The region's viral vectors and plasmid DNA market is boosted by the presence of a huge population base, government measures to develop healthcare facilities, and a rise in healthcare expenditure.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc

Strategies deployed in Cancer Gene Therapy Market

• Apr-2022: Kite, a Gilead Company received approval from U.S. Food and Drug Administration (FDA) for Yescarta CAR T-cell therapy. This approval focused on adult patients with huge B-cell lymphoma that is disobedient to first-line chemoimmunotherapy or that worsen within 12 months of starting chemoimmunotherapy.
• Mar-2022: Novartis signed an agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics. This agreement aimed to launch HER 2 targeted CAR-M cell therapy, which is certified in basic tests for the therapy of solid tumors. Additionally, The Global Biotech Cooperations unit of Novartis is completed engaged to collaborate with Carisma Therapeutics to carry CAR-M cell treatments to patients by providing its proven state-of-the-art cell and gene manufacturing abilities. 
• Dec-2021: Novartis signed an agreement to acquire Gyroscope Therapeutics, a clinical-stage gene therapy company. Through this acquisition, Novartis is expected to achieve access to the prior guide experimental gene treatment, GT005.
• Dec-2021: Novartis unveiled T-Charge, the organization's next-generation CAR-T platform. The platform is expected to offer a base for diverse new investigational CAR-T cell treatments in the Novartis pipeline. Additionally, the T-Charge platform conserves T cell stemness, the capabilities to mature and renew, which results in a product embracing greater proliferative potential and lesser exhausted T cells. Moreover, T-Charge, CAR-T cell growth occurs mainly within a patient's body, reducing the need for an extended culture time outside of the body. Furthermore, the unique attribute of the T-Charge platform may guide to superior and more strong responses, enhance long-term conclusion and a minimize danger of harsh adverse events.
• Mar-2021: Novartis received an approval from Health Sciences Authority for Kymriah as the first economic chimeric antigen receptor T-cell therapy. Additionally, Kymriah, a CD19-directed constitutionally customized autologous T-cell immunocellular therapy, is accepted to treat two fatal cancers that have restricted treatment choices and historically worst conclusions, addressing the crucial demand for new treatments for patients.
• Mar-2021: Bristol Myers Squibb along with bluebird bio received a U.S. Food and Drug Administration has approved Abecma, as the first B-cell maturation antigen directed chimeric antigen receptor T cell immunotherapy. The approval offers medication for adult patients with refractory or relapsed various myeloma after four or more preceding lines of therapy, such as a proteasome inhibitor, an anti-CD38 monoclonal antibody, and an immunomodulatory agent. Additionally, Abecma is a customized immune cell therapy accepted as a one-time mixture with an approved dose range of 300 to 460 x 106 CAR-positive T cells.
• Jan-2020: Adapta Immue signed a co-development and co-commercialization agreement with Astellas Pharma, a Japanese multinational pharmaceutical company. Through this agreement, the companies aimed to launch new stem-cell concluded allogeneic T-cell therapies for patients with cancer. Additionally, the collaboration is expected to use Adaptimmune's target recognition and affirmation abilities for creating target-specific chimeric antigen receptors, HLA-independent TCRs, and T-cell Receptors that identify surface epitopes freely of the HLA overview of the tumor cell.
• Oct-2019: GlaxoSmithKline joined hands with Lyell Immunopharma, operator of a biotechnology company. Through this collaboration, the companies aimed to enhance cell therapies for cancer patients. Additionally, the collaboration is expected to approach Lyell's technologies to further reinforce GSK's cell treatment pipeline, such as GSK3377794, which marks the NY-ESO-1 antigen that is announced around various cancer types.
• Mar-2019: Bristol-Myers Squibb merged with Celgene, a pharmaceutical company that makes cancer and immunology drugs. Through this merger, Bristol-Myers Squibb is expected to acquire Celgene to build a dominant concentrated specialty biopharma enterprise well positioned to meet the demands of patients with cancer, immunologic, inflammatory disease, and cardiovascular disease through great value creative medicines and dominating scientific abilities. Additionally, the integrated enterprise is expected to provide global scale and reach, preserving the agility and speed that is core to each enterprise's strategic access.

Scope of the Study

Market Segments Covered in the Report:

By Therapy

• Gene Induced Immunotherapy
• Oncolytic Virotherapy, and
• Gene Transfer

By End User

• Hospitals
• Diagnostic centers
• Research Institutes

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Novartis AG
• GlaxoSmithKline PLC (GSK)
• Amgen, Inc.
• Bristol Myers Squibb Company
• Karyopharm Therapeutics, Inc.
• Gilead Sciences, Inc.
• Adaptimmune Limited
• Genelux Corporation
• Sarepta Therapeutics, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free